Fisher Asset Management LLC Has $12.41 Million Position in Myriad Genetics, Inc. (NASDAQ:MYGN)

Fisher Asset Management LLC grew its holdings in shares of Myriad Genetics, Inc. (NASDAQ:MYGN - Free Report) by 50.2% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 905,209 shares of the company's stock after purchasing an additional 302,367 shares during the period. Fisher Asset Management LLC owned 0.99% of Myriad Genetics worth $12,410,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of the business. Point72 Hong Kong Ltd bought a new stake in Myriad Genetics in the third quarter valued at $32,000. KBC Group NV boosted its stake in Myriad Genetics by 132.8% during the 4th quarter. KBC Group NV now owns 5,845 shares of the company's stock valued at $80,000 after purchasing an additional 3,334 shares during the period. Mirae Asset Global Investments Co. Ltd. grew its position in Myriad Genetics by 21.6% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,285 shares of the company's stock worth $87,000 after purchasing an additional 583 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. increased its stake in shares of Myriad Genetics by 43.8% in the third quarter. Point72 Asia Singapore Pte. Ltd. now owns 4,833 shares of the company's stock valued at $132,000 after purchasing an additional 1,471 shares during the period. Finally, Meeder Asset Management Inc. raised its holdings in shares of Myriad Genetics by 588.4% during the third quarter. Meeder Asset Management Inc. now owns 4,922 shares of the company's stock valued at $135,000 after buying an additional 4,207 shares during the last quarter. 99.02% of the stock is currently owned by institutional investors.

Remove Ads

Wall Street Analyst Weigh In

A number of research analysts have recently commented on MYGN shares. Leerink Partners lowered Myriad Genetics from an "outperform" rating to a "market perform" rating and lowered their price target for the company from $30.00 to $21.00 in a report on Monday, December 9th. UBS Group reduced their price target on shares of Myriad Genetics from $18.00 to $16.00 and set a "neutral" rating for the company in a research note on Tuesday, February 25th. Raymond James reiterated an "outperform" rating and issued a $19.00 price objective (down from $27.00) on shares of Myriad Genetics in a report on Tuesday, February 25th. Piper Sandler dropped their target price on Myriad Genetics from $14.00 to $11.50 and set a "neutral" rating on the stock in a report on Tuesday. Finally, Stephens reaffirmed an "equal weight" rating and set a $20.00 price target on shares of Myriad Genetics in a research note on Thursday, January 16th. Three equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating and five have assigned a buy rating to the company. According to MarketBeat.com, the company has a consensus rating of "Hold" and an average price target of $21.82.

Myriad Genetics Trading Down 3.2 %

Shares of NASDAQ MYGN traded down $0.34 during mid-day trading on Friday, hitting $10.18. 819,577 shares of the company traded hands, compared to its average volume of 1,155,522. The company has a quick ratio of 1.73, a current ratio of 1.90 and a debt-to-equity ratio of 0.05. Myriad Genetics, Inc. has a 1 year low of $9.76 and a 1 year high of $29.30. The stock has a market capitalization of $926.74 million, a price-to-earnings ratio of -7.83 and a beta of 1.88. The business has a 50 day moving average of $13.02 and a two-hundred day moving average of $18.55.

Myriad Genetics (NASDAQ:MYGN - Get Free Report) last posted its quarterly earnings data on Tuesday, February 25th. The company reported ($0.09) EPS for the quarter, missing analysts' consensus estimates of $0.03 by ($0.12). The firm had revenue of $210.60 million for the quarter, compared to analysts' expectations of $210.35 million. Myriad Genetics had a negative net margin of 14.09% and a negative return on equity of 4.51%. During the same period in the prior year, the company posted ($0.12) earnings per share. On average, sell-side analysts anticipate that Myriad Genetics, Inc. will post -0.3 earnings per share for the current fiscal year.

Myriad Genetics Profile

Myriad Genetics, Inc, a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer.